Forward-Looking StatementsZogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding Migranal Nasal Spray's and SUMAVEL DosePro's usefulness as a therapeutic option in relieving migraine pain and symptoms, the potential for the co-promotion arrangement to help Zogenix achieve profitability and the possibility of adding complementary migraine therapies to Zogenix's product portfolio. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: Zogenix's ability to successfully sell Migranal Nasal Spray to Zogenix's base of prescribers; unexpected adverse side effects relating to Migranal Nasal Spray that could result in recalls or product liability claims; the potential early termination of the co-promote arrangement; and other risks described in the company's prior press releases and filings with the Securities and Exchange Commission.
Zogenix Begins Promotion Of Migranal(R) Nasal Spray
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts